2seventy bio Statistics
Total Valuation
2seventy bio has a market cap or net worth of $247.71 million. The enterprise value is $297.23 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, before market open.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
2seventy bio has 51.50 million shares outstanding. The number of shares has increased by 20.40% in one year.
Shares Outstanding | 51.50M |
Shares Change (YoY) | +20.40% |
Shares Change (QoQ) | +5.65% |
Owned by Insiders (%) | 2.91% |
Owned by Institutions (%) | 93.04% |
Float | 50.00M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.64 |
Forward PS | 2.25 |
PB Ratio | 1.05 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 6.74 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.76, with a Debt / Equity ratio of 1.07.
Current Ratio | 4.76 |
Quick Ratio | 4.66 |
Debt / Equity | 1.07 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.89% and return on invested capital (ROIC) is -20.82%.
Return on Equity (ROE) | -51.89% |
Return on Assets (ROA) | -19.01% |
Return on Capital (ROIC) | -20.82% |
Revenue Per Employee | $161,022 |
Profits Per Employee | -$570,270 |
Employee Count | 274 |
Asset Turnover | 0.07 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +123.72% in the last 52 weeks. The beta is 1.78, so 2seventy bio's price volatility has been higher than the market average.
Beta (5Y) | 1.78 |
52-Week Price Change | +123.72% |
50-Day Moving Average | 4.76 |
200-Day Moving Average | 4.64 |
Relative Strength Index (RSI) | 47.84 |
Average Volume (20 Days) | 227,120 |
Short Selling Information
The latest short interest is 5.42 million, so 10.52% of the outstanding shares have been sold short.
Short Interest | 5.42M |
Short Previous Month | 5.32M |
Short % of Shares Out | 10.52% |
Short % of Float | 10.84% |
Short Ratio (days to cover) | 16.29 |
Income Statement
In the last 12 months, 2seventy bio had revenue of $44.12 million and -$156.25 million in losses. Loss per share was -$3.02.
Revenue | 44.12M |
Gross Profit | -134.41M |
Operating Income | -186.14M |
Pretax Income | -156.25M |
Net Income | -156.25M |
EBITDA | -176.56M |
EBIT | -186.14M |
Loss Per Share | -$3.02 |
Full Income Statement Balance Sheet
The company has $201.87 million in cash and $251.40 million in debt, giving a net cash position of -$49.52 million or -$0.96 per share.
Cash & Cash Equivalents | 201.87M |
Total Debt | 251.40M |
Net Cash | -49.52M |
Net Cash Per Share | -$0.96 |
Equity (Book Value) | 234.80M |
Book Value Per Share | 4.56 |
Working Capital | 177.67M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$150.13 million and capital expenditures -$4.49 million, giving a free cash flow of -$154.61 million.
Operating Cash Flow | -150.13M |
Capital Expenditures | -4.49M |
Free Cash Flow | -154.61M |
FCF Per Share | -$3.00 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -421.88% |
Pretax Margin | -354.16% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -350.04% |
Dividends & Yields
2seventy bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -20.40% |
Shareholder Yield | -20.40% |
Earnings Yield | -63.08% |
FCF Yield | -62.42% |
Analyst Forecast
The average price target for 2seventy bio is $10.40, which is 116.22% higher than the current price. The consensus rating is "Buy".
Price Target | $10.40 |
Price Target Difference | 116.22% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 12.47% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
2seventy bio has an Altman Z-Score of -1.64 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.64 |
Piotroski F-Score | 1 |